Pretax income is the income that a company earns before paying income taxes. Altimmune's pretax income for the
three
months ended in Dec. 2023 was $-31.64 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-88.45 Mil.
Altimmune's pretax margin was -85,516.22%.
During the past 13 years, Altimmune's highest Pretax Margin was 124867.65%. The lowest was -20762.21%. And the median was -461.78%.
Altimmune Pre-Tax Income Historical Data
The historical data trend for Altimmune's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Altimmune's Pre-Tax Income
For the Biotechnology subindustry, Altimmune's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altimmune's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altimmune's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Altimmune's Pre-Tax Income falls into.
Altimmune Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Altimmune's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altimmune (NAS:ALT) Pre-Tax Income Explanation
Altimmune's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Altimmune's highest Pretax Margin was 124867.65%. The lowest was -20762.21%. And the median was -461.78%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altimmune Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Altimmune's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALT has been successfully added to your 